Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease

Despite new therapeutic options, treatment of steroid-refractory chronic graft-versus-host disease (SR-cGVHD) remains challenging as organ involvement and clinical manifestations are highly variable. In previous trials of low-dose interleukin-2 (LD IL-2), we established the safety and efficacy of LD...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Haesook T., Koreth, John, Whangbo, Jennifer, Nikiforow, Sarah, Reynolds, Carol G., Stowe, Peter, Ho, Vincent T., Cutler, Corey, Antin, Joseph H., Soiffer, Robert J., Ritz, Jerome
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636330/
https://www.ncbi.nlm.nih.gov/pubmed/35617682
http://dx.doi.org/10.1182/bloodadvances.2022007773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636330/
https://www.ncbi.nlm.nih.gov/pubmed/35617682
http://dx.doi.org/10.1182/bloodadvances.2022007773

Ejemplares similares